(Q34339890)

1 August 2017

0 references

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis (English)

1 reference

non-small-cell lung carcinoma

1 August 2017

0 references

1 reference

Chee Khoon Lee

1

0 references

James Chih-Hsin Yang

James Chih-Hsin Yang

17

0 references

Chris Brown

Chris Brown

2

0 references

James Chung-Man Ho

James Chung-Man Ho

8

0 references

Siow-Ming Lee

Siow Ming Lee

15

0 references

author name string

Richard J Gralla

3

1 reference

1 August 2017

Vera Hirsh

4

1 reference

1 August 2017

Sumitra Thongprasert

5

1 reference

1 August 2017

Chun-Ming Tsai

6

1 reference

1 August 2017

Eng Huat Tan

7

1 reference

1 August 2017

Da Tong Chu

9

1 reference

1 August 2017

Adel Zaatar

10

1 reference

1 August 2017

Jemela Anne Osorio Sanchez

11

1 reference

1 August 2017

Vu Van Vu

12

1 reference

1 August 2017

Joseph Siu Kie Au

13

1 reference

1 August 2017

Akira Inoue

14

1 reference

1 August 2017

Val Gebski

16

1 reference

1 August 2017

language of work or name

English

0 references

publication date

17 April 2013

1 reference

Journal of the National Cancer Institute

1 August 2017

published in

1 reference

1 August 2017

volume

105

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

595-605

1 reference

A translational view of the molecular pathogenesis of lung cancer

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Lung cancer in never smokers--a different disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Standardversus adaptive monitoring procedures: a commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Issues in using progression-free survival when evaluating oncology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT072

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT072

1 reference

1 August 2017

1 reference